Ventyx Biosciences (VTYX) to Release Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Ventyx Biosciences Stock Performance

Shares of Ventyx Biosciences stock opened at $13.96 on Thursday. Ventyx Biosciences has a one year low of $0.78 and a one year high of $25.00. The business has a 50-day simple moving average of $11.94 and a 200-day simple moving average of $7.51. The company has a market cap of $1.00 billion, a PE ratio of -9.31 and a beta of 1.25.

Wall Street Analyst Weigh In

VTYX has been the subject of a number of analyst reports. HC Wainwright downgraded shares of Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price for the company. in a research note on Thursday, January 8th. UBS Group reaffirmed a “neutral” rating and set a $14.00 price objective (down from $20.00) on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Lifesci Capital reissued a “market perform” rating and set a $14.00 target price on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Wells Fargo & Company restated an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Finally, Clear Str cut shares of Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Eight equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $14.00.

Insiders Place Their Bets

In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider directly owned 489,481 shares in the company, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. The trade was a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 14.49% of the company’s stock.

Institutional Trading of Ventyx Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTYX. Hudson Bay Capital Management LP acquired a new position in Ventyx Biosciences during the second quarter worth about $34,000. Engineers Gate Manager LP purchased a new stake in Ventyx Biosciences during the second quarter worth $42,000. Jump Financial LLC acquired a new stake in Ventyx Biosciences in the second quarter valued at $53,000. Jane Street Group LLC purchased a new position in shares of Ventyx Biosciences in the first quarter valued at $56,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Ventyx Biosciences during the 2nd quarter worth $60,000. 97.88% of the stock is owned by hedge funds and other institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.